Related Experiment Video
Updated: Jun 24, 2026
14:45
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
MYO6 Activates cGAS-STING Pathway in CD4+ T Cell to Accelerate Parkinson's Disease
Yuanyuan Wang1, Guoqing Wang1, Zhongxian Sun1
1Joint International Research Laboratory of Ethnomedicine of Ministry of Education and Key Laboratory of Basic Pharmacology of Ministry of Education and Key Laboratory of Basic Pharmacology of Guizhou Province and Laboratory Animal Center, Zunyi Medical University, Zunyi, Guizhou, 563000, China.
Current Neuropharmacology
|June 23, 2026
Summary
Parkinson's disease involves CD4+ T cells and the cGAS-STING pathway. Myosin VI (MYO6) in CD4+ T cells drives neuroinflammation and dopamine neuron loss via this pathway, suggesting MYO6 as a therapeutic target.
Area of Science:
- Neuroimmunology
- Cellular Biology
- Molecular Medicine
Background:
- Immune system dysfunction, particularly CD4+ T cells, contributes to dopamine (DA) neuron loss in Parkinson's Disease (PD).
- The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is implicated in immune regulation and may play a role in PD pathogenesis.
Purpose of the Study:
- To elucidate the specific function of the cGAS-STING pathway in CD4+ T cells within the context of PD.
- To investigate the potential contribution of this pathway to the development of PD pathology.
Main Methods:
- Proteomic analysis identified Myosin VI (MYO6) as a commonly upregulated protein in CD4+ T cells from PD mice.
- Western blot assays were used to measure the expression of MYO6 and cGAS-STING pathway components.
Main Results:
- Upregulated MYO6 expression correlated with activation of the cGAS-STING pathway (cGAS, p-STING/STING, p-TBK1/TBK1, p-IRF3/IRF3) and increased IL-6 and iNOS in CD4+ T cells from PD mice.
- Deletion of MYO6 or TBK1 in CD4+ T cells reduced neuroinflammation and DA neuronal death.
- MYO6 was identified as a novel upstream regulator of TBK1.
Conclusions:
- A signaling cascade involving MYO6, cGAS-STING, and TBK1 contributes to PD progression.
- MYO6 presents a potential therapeutic target within CD4+ T cells for treating PD.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:25cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...